v3.25.3
Summary of Significant Accounting Policies - Narrative (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 17, 2021
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Product
$ / shares
shares
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Sep. 26, 2022
$ / shares
shares
Summary Of Significant Accounting Policies [Line Items]              
Number of preclinical products in development | Product       3      
Allowance for doubtful accounts           $ 100,000  
Allowance for credit losses   $ 0   $ 0   0  
Receivables written off       0   0  
Depreciation   5,600 $ 46,700 78,000 $ 146,000    
Loss contingency accrual   $ 0   $ 0   $ 0  
Employee Stock Option              
Summary Of Significant Accounting Policies [Line Items]              
Anti-dilutive securities excluded from computation of earnings per share (in shares) | shares       3,805,985      
Employee Stock Purchase Plan              
Summary Of Significant Accounting Policies [Line Items]              
Offering period 6 months     6 months      
Private Placement Financing | Purchase Agreement | Pre-Funded Warrant              
Summary Of Significant Accounting Policies [Line Items]              
Number of warrants issued to purchase common stock (in shares) | shares             2,426,493
Warrants exercise price (in dollars per share) | $ / shares   $ 0.0001   $ 0.0001     $ 0.0001
Private Placement Financing | Purchase Agreement | Pre-Funded Warrant - March 2025              
Summary Of Significant Accounting Policies [Line Items]              
Number of warrants issued to purchase common stock (in shares) | shares   20,076,500   20,076,500      
Private Placement Financing | Purchase Agreement | Pre-Funded Warrant - September 2022              
Summary Of Significant Accounting Policies [Line Items]              
Number of warrants issued to purchase common stock (in shares) | shares   2,000,037   2,000,037      
Product Sales Allowance              
Summary Of Significant Accounting Policies [Line Items]              
Deduction from gross product sales for allowances   $ 0 $ 1,710,000 $ 2,085,000 $ 4,695,000    
Minimum              
Summary Of Significant Accounting Policies [Line Items]              
Property and equipment estimated useful lives   3 years   3 years      
Maximum              
Summary Of Significant Accounting Policies [Line Items]              
Property and equipment estimated useful lives   5 years   5 years      
Term of options granted       10 years      
Customer One | Revenue Benchmark | Customer Concentration Risk              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk percentage     54.00% 37.00% 55.00%    
Customer One | Accounts Receivable | Customer Concentration Risk              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk percentage           42.00%  
Customer Two | Revenue Benchmark | Customer Concentration Risk              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk percentage     44.00% 60.00% 44.00%    
Customer Two | Accounts Receivable | Customer Concentration Risk              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk percentage           56.00%